Introduction: Who Should Undergo EGFR Diagnostics

If you receive a diagnosis of non-small cell lung cancer, your doctor will likely recommend testing to see if your cancer cells carry specific genetic changes. One of the most important changes to look for is a mutation in the EGFR gene, which stands for epidermal growth factor receptor. This protein normally helps cells grow and divide, but when it mutates, it can drive cancer cells to grow uncontrollably.^[1]

Not everyone with lung cancer needs EGFR testing right away, but certain groups of people are more likely to benefit from this diagnostic step. Testing is especially important for anyone diagnosed with lung adenocarcinoma, a type of non-small cell lung cancer that makes up more than half of all lung cancer cases. Doctors strongly recommend comprehensive testing for all patients with this diagnosis, regardless of their smoking history or other characteristics.^[2]

EGFR mutations are found in roughly 10 to 15 percent of lung cancer cases in the United States. However, this percentage varies widely depending on who you are. Women are more likely to have EGFR-positive lung cancer than men. People who have never smoked or only smoked a little are also at higher risk—among nonsmokers with non-small cell lung cancer, EGFR mutations appear in about 36 percent of cases. Young adults with lung cancer are another group where EGFR mutations are surprisingly common, present in approximately 50 percent of cases. People of Asian or East Asian heritage also face higher rates, with EGFR mutations detected in 30 to 50 percent of their lung cancers compared to 10 to 15 percent in white populations.^[3][6]

Even if you do not fit into these higher-risk groups, your doctor may still recommend EGFR testing. The mutation can appear in anyone with non-small cell lung cancer, and discovering it early opens the door to targeted treatments that may be more effective and have fewer side effects than standard chemotherapy.^[5]

Diagnostic Methods for Identifying EGFR Mutations

Once your doctor suspects or confirms lung cancer, the next step is to determine whether your cancer carries an EGFR mutation. This process involves taking a sample of your cancer cells and analyzing them in a laboratory. The two main approaches are called tissue biopsy and liquid biopsy, and each serves an important role in the diagnostic process.^[2]

Tissue Biopsy

A tissue biopsy is the most common and reliable method for detecting EGFR mutations. During this procedure, a doctor removes a small sample of tissue from your lung tumor. This can be done in several ways depending on where the tumor is located and how accessible it is. Some doctors use a needle inserted through the chest wall to reach the tumor. Others may use a bronchoscope, which is a thin, flexible tube passed through your mouth or nose into your lungs to collect the sample.^[13]

In many cases, if you already had a biopsy to diagnose your lung cancer in the first place, that same tissue sample can be used for EGFR testing. This means you may not need a second procedure. The laboratory will examine the genetic makeup of the cancer cells, looking specifically for changes in the EGFR gene. This process is often called comprehensive biomarker testing because it checks not only for EGFR but also for other important genetic changes that might affect your treatment options.^[6]

Liquid Biopsy

A liquid biopsy is a newer, less invasive alternative that involves taking a sample of your blood rather than tissue from the tumor itself. Cancer cells sometimes release small fragments of their genetic material into the bloodstream, and advanced laboratory techniques can detect these fragments. A liquid biopsy can identify EGFR mutations by analyzing these circulating pieces of cancer DNA.^[8]

Liquid biopsies are especially useful when a tissue biopsy is not possible or when there is not enough tissue available for testing. For example, some tumors are located in areas that are difficult to reach safely, or a previous biopsy may not have provided enough material for complete testing. Liquid biopsies are also used later in treatment to monitor whether the cancer has developed resistance to therapy.^[6]

Although liquid biopsies are becoming more accurate and are showing great potential, tissue biopsies remain the standard of care when enough tissue is available. Your doctor will decide which method is best for your specific situation.^[2]

Next-Generation Sequencing

Not all laboratory tests are equally capable of detecting EGFR mutations. Some older testing methods may miss certain types of mutations, particularly rare ones. For this reason, experts recommend using a technique called next-generation sequencing. This advanced method can identify a wide range of genetic changes, including less common EGFR mutations that might otherwise go undetected.^[25]

If your doctor orders biomarker testing, it is a good idea to ask the laboratory to use next-generation sequencing. This approach provides the most complete picture of your cancer’s genetic profile and helps your care team choose the most appropriate treatment.^[8]

Types of EGFR Mutations

There are more than 70 different types of EGFR mutations, and they do not all behave the same way. Some are more common than others, and some respond better to certain treatments. The most frequently found mutations are deletions in a region called exon 19 and a change known as the L858R point mutation in exon 21. Together, these two types account for nearly 90 percent of all EGFR mutations found in lung cancer.^[6][8]

Other EGFR mutations are less common but still important. For example, exon 20 insertions are found in about 10 percent of EGFR-positive cases and tend to respond differently to treatments compared to the more common mutations. There is also a mutation called T790M, which often appears after a patient has been treated with certain EGFR-targeted drugs and develops resistance. Identifying which specific type of mutation you have is crucial because it directly influences which therapies will be most effective.^[6][8]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or new ways of using existing treatments. For patients with EGFR-positive lung cancer, clinical trials can offer access to cutting-edge therapies that are not yet widely available. However, enrolling in a clinical trial requires meeting specific criteria, and diagnostic testing plays a central role in determining whether you qualify.

Confirming EGFR Status

The first and most important requirement for most EGFR-related clinical trials is proof that your lung cancer carries an EGFR mutation. Researchers need to know your exact mutation type because different trials target different mutations. For example, a trial testing a new drug for exon 19 deletions may not accept patients with exon 20 insertions. Your diagnostic test results, including the specific type of EGFR mutation you have, will be reviewed by the trial team to confirm your eligibility.^[6]

Staging and Additional Testing

Clinical trials often have strict rules about the stage of cancer they will accept. Some trials are only open to patients with advanced or metastatic disease, while others may include earlier stages. Your doctors will use imaging studies such as CT scans, PET scans, or MRI scans to determine the stage of your cancer and whether it has spread to other parts of your body. These imaging tests provide detailed pictures of your lungs, lymph nodes, and other organs, helping the research team understand the extent of your disease.^[8]

In addition to confirming your EGFR mutation and cancer stage, some trials may require additional tests to assess your overall health. Blood tests can check your kidney and liver function, blood cell counts, and other important markers. These results help researchers ensure that you are healthy enough to tolerate the experimental treatment being studied.

Monitoring for Resistance Mutations

If you have already been treated with an EGFR-targeted drug and your cancer has started growing again, you may be eligible for trials testing newer treatments designed to overcome resistance. In these cases, additional diagnostic testing is often needed. Doctors may perform another biopsy or liquid biopsy to look for new mutations that have developed, such as the T790M mutation or other changes that allow cancer cells to resist treatment. Identifying these resistance mutations is essential for matching you with the right clinical trial.^[5][15]

Comprehensive Biomarker Testing

Many clinical trials recommend or require comprehensive biomarker testing, which looks for a broad range of genetic changes beyond just EGFR. Current guidelines from organizations such as the National Comprehensive Cancer Network suggest testing for at least eight different biomarkers in patients with non-small cell lung cancer. This comprehensive approach ensures that researchers have a complete understanding of your cancer’s biology and can determine whether you might benefit from other targeted therapies or combination treatments being studied in trials.^[2][13]